Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells–Single Center Experience
The most effective treatment of steroid refractory acute graft vs. host disease (aGvHD) is not yet established and mesenchymal stem cells (MSC) appear to be a promising therapy for the condition. We report single center case series of three patients, who underwent allogeneic hematopoietic cell trans...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-07-01
|
| Series: | Frontiers in Bioengineering and Biotechnology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fbioe.2018.00093/full |
| _version_ | 1811269717362475008 |
|---|---|
| author | Maja Česen Mazič Lenart Girandon Miomir Kneževič Simona L. Avčin Janez Jazbec |
| author_facet | Maja Česen Mazič Lenart Girandon Miomir Kneževič Simona L. Avčin Janez Jazbec |
| author_sort | Maja Česen Mazič |
| collection | DOAJ |
| description | The most effective treatment of steroid refractory acute graft vs. host disease (aGvHD) is not yet established and mesenchymal stem cells (MSC) appear to be a promising therapy for the condition. We report single center case series of three patients, who underwent allogeneic hematopoietic cell transplantation and later developed steroid refractory graft-vs.-host disease, treated with MSC infusions. Two patients achieved complete remission and one patient partial remission of skin and/or gastrointestinal aGvHD. We demonstrated application of MSC for treatment of severe steroid refractory aGvHD is feasible in clinical practice. Detailed description of patient's features and MSC production protocol is crucial for future comparison on efficacy and safety of cell-based therapies. However, for any substantial conclusions regarding efficacy of MSC higher patient numbers will be required. |
| first_indexed | 2024-04-12T21:47:00Z |
| format | Article |
| id | doaj.art-e568546c7c944b7eaee9eb5e73cf3ff0 |
| institution | Directory Open Access Journal |
| issn | 2296-4185 |
| language | English |
| last_indexed | 2024-04-12T21:47:00Z |
| publishDate | 2018-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Bioengineering and Biotechnology |
| spelling | doaj.art-e568546c7c944b7eaee9eb5e73cf3ff02022-12-22T03:15:36ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852018-07-01610.3389/fbioe.2018.00093366396Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells–Single Center ExperienceMaja Česen Mazič0Lenart Girandon1Miomir Kneževič2Simona L. Avčin3Janez Jazbec4Department for Pediatric Hematology and Oncology, University Children Hospital Ljubljana, Ljubljana, SloveniaEducell Ltd., Ljubljana, SloveniaEducell Ltd., Ljubljana, SloveniaDepartment for Pediatric Hematology and Oncology, University Children Hospital Ljubljana, Ljubljana, SloveniaDepartment for Pediatric Hematology and Oncology, University Children Hospital Ljubljana, Ljubljana, SloveniaThe most effective treatment of steroid refractory acute graft vs. host disease (aGvHD) is not yet established and mesenchymal stem cells (MSC) appear to be a promising therapy for the condition. We report single center case series of three patients, who underwent allogeneic hematopoietic cell transplantation and later developed steroid refractory graft-vs.-host disease, treated with MSC infusions. Two patients achieved complete remission and one patient partial remission of skin and/or gastrointestinal aGvHD. We demonstrated application of MSC for treatment of severe steroid refractory aGvHD is feasible in clinical practice. Detailed description of patient's features and MSC production protocol is crucial for future comparison on efficacy and safety of cell-based therapies. However, for any substantial conclusions regarding efficacy of MSC higher patient numbers will be required.https://www.frontiersin.org/article/10.3389/fbioe.2018.00093/fullimmunosuppressive therapystem cellpediatricsGvHDregenerationremission induction |
| spellingShingle | Maja Česen Mazič Lenart Girandon Miomir Kneževič Simona L. Avčin Janez Jazbec Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells–Single Center Experience Frontiers in Bioengineering and Biotechnology immunosuppressive therapy stem cell pediatrics GvHD regeneration remission induction |
| title | Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells–Single Center Experience |
| title_full | Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells–Single Center Experience |
| title_fullStr | Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells–Single Center Experience |
| title_full_unstemmed | Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells–Single Center Experience |
| title_short | Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells–Single Center Experience |
| title_sort | treatment of severe steroid refractory acute graft vs host disease with mesenchymal stem cells single center experience |
| topic | immunosuppressive therapy stem cell pediatrics GvHD regeneration remission induction |
| url | https://www.frontiersin.org/article/10.3389/fbioe.2018.00093/full |
| work_keys_str_mv | AT majacesenmazic treatmentofseveresteroidrefractoryacutegraftvshostdiseasewithmesenchymalstemcellssinglecenterexperience AT lenartgirandon treatmentofseveresteroidrefractoryacutegraftvshostdiseasewithmesenchymalstemcellssinglecenterexperience AT miomirknezevic treatmentofseveresteroidrefractoryacutegraftvshostdiseasewithmesenchymalstemcellssinglecenterexperience AT simonalavcin treatmentofseveresteroidrefractoryacutegraftvshostdiseasewithmesenchymalstemcellssinglecenterexperience AT janezjazbec treatmentofseveresteroidrefractoryacutegraftvshostdiseasewithmesenchymalstemcellssinglecenterexperience |